Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.709
Sell
RSI(14)
36.606
Neutral
STOCH(KDJ)(9,3,3)
21.826
Neutral
ATR(14)
11.787
Low Volatility
CCI(14)
-194.844
Sell
Williams %R
88.467
Oversold
TRIX(12,20)
-0.181
Sell
StochRSI(14)
0.000
Sell
Search
United Therapeutics Corp
UTHRAdd to Watchlist
517.380USD
-8.440-1.61%
Close 07-31 16:00（ET）Quotes delayed by 15 min
21.81BMarket Cap
17.67P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.61%
5 Days
-2.10%
1 Month
-4.51%
6 Months
+10.20%
Year to Date
+6.18%
1 Year
+88.34%
Key Figures
525.820Open
525.820High
616.62KVolume
17.67P/E TTM
15.01P/E Dynamic
--Dividend TTM
1.46%Turnover Ratio
525.820Prev. Close
514.340Low
273.39MTurnover
18.25P/E Static
3.70P/B
0.00%Div Yield TTM
17.81%ROA
609.35052wk High
1.39Volume Ratio
1.20BNet Profit
42.16MShares
29.2723EPS TTM
0.58Beta
20.26%ROE
272.12052wk Low
2.18%Amplitude
82.93%Gross Margin
21.81BMarket Cap
-2.94Reward/Risk
1.84%Risk Rate
TradingKey Stock Score of United Therapeutics Corp
Currency: USD Updated: 2026-07-31Key Insights
United Therapeutics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 665.86.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
United Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
United Therapeutics Corp Highlights
StrengthsRisks
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36.74% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.18B.
Overvalued
The company’s latest PE is 17.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.91M shares, decreasing 3.19% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
665.863
Target Price
+26.90%
Upside Space
United Therapeutics Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
16
analysts
Buy
Current Rating
665.863
Target Price
+26.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
United Therapeutics Corp
UTHR
16
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
523.960
Sell
MA10
527.004
Sell
MA20
534.680
Sell
MA50
544.384
Sell
MA100
553.510
Sell
MA200
514.393
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
United Therapeutics Corp Info
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Ticker SymbolUTHR
CompanyUnited Therapeutics Corp
CEORothblatt (Martine A)
Websitehttps://www.unither.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of United Therapeutics Corp (UTHR)?
The current price of United Therapeutics Corp (UTHR) is 517.38.
What is the symbol of United Therapeutics Corp?
The ticker symbol of United Therapeutics Corp is UTHR.
What is the 52-week high of United Therapeutics Corp?
The 52-week high of United Therapeutics Corp is 609.35.
What is the 52-week low of United Therapeutics Corp?
The 52-week low of United Therapeutics Corp is 272.12.
What is the market capitalization of United Therapeutics Corp?
The market capitalization of United Therapeutics Corp is 21.81B.
Is United Therapeutics Corp (UTHR) currently rated as Buy, Hold, or Sell?
According to analysts, United Therapeutics Corp (UTHR) has an overall rating of Buy, with a price target of 665.86.
What is the Earnings Per Share (EPS TTM) of United Therapeutics Corp (UTHR)?
The Earnings Per Share (EPS TTM) of United Therapeutics Corp (UTHR) is 30.13.